Crispr Therapeutics (NASDAQ:CRSP) was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating in a research note issued to investors on Tuesday, November 19th, MarketBeat reports.
A number of other analysts also recently issued reports on the stock. Goldman Sachs Group raised their price objective on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a report on Tuesday, November 19th. Barclays raised their price objective on shares of Crispr Therapeutics from $59.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Jefferies Financial Group started coverage on shares of Crispr Therapeutics in a report on Thursday, August 1st. They set a “buy” rating and a $64.00 price objective for the company. BidaskClub upgraded shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, November 15th. Finally, Chardan Capital reiterated a “buy” rating and set a $72.50 target price on shares of Crispr Therapeutics in a research report on Monday, November 18th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $69.54.
NASDAQ CRSP traded down $0.67 on Tuesday, hitting $65.36. 739,399 shares of the company were exchanged, compared to its average volume of 712,268. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The stock has a fifty day moving average of $58.41 and a 200-day moving average of $48.30. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $74.00. The company has a market cap of $3.62 billion, a PE ratio of -19.00 and a beta of 3.31.
Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. On average, analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total transaction of $390,000.00. Following the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at $390,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Insiders sold 56,118 shares of company stock worth $3,620,760 over the last ninety days. 21.40% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the stock. NEXT Financial Group Inc boosted its holdings in Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after acquiring an additional 549 shares in the last quarter. Benjamin Edwards Inc. boosted its holdings in Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after acquiring an additional 268 shares in the last quarter. Coastal Investment Advisors Inc. bought a new stake in Crispr Therapeutics in the third quarter valued at $26,000. US Bancorp DE boosted its holdings in Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after acquiring an additional 526 shares in the last quarter. Finally, BSW Wealth Partners bought a new stake in Crispr Therapeutics in the second quarter valued at $39,000. Institutional investors and hedge funds own 49.82% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: Book Value Of Equity Per Share – BVPS Explained
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.